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Abstract
We conducted a nationwide retrospective study to evaluate clin-
ical characteristics and outcome of mucormycosis among alloge-
neic haematopoietic stem cell transplant recipients. Twenty-nine
patients were diagnosed between 2003 and 2008. Mucormycosis
occurred at a median of 225 days after allogeneic haematopoiet-
ic stem cell transplant, and as a breakthrough infection in 23
cases. Twenty-six patients were receiving steroids, mainly for
graft-versus-host disease treatment, while ten had experienced a
prior post-transplant invasive fungal infection. Twenty-six
patients received an antifungal treatment; surgery was performed
in 12. Overall survival was 34% at 3 months and 17% at 1 year.
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Introduction
Since the 1990s, an increasing incidence of mucormycosis
(MCM) has been reported, particularly among patients trea-
ted for haematological malignancies and allogeneic haemato-
poietic stem cell transplant (HSCT) recipients [1–7]. To
further assess the clinical characteristics and outcome of
MCM in the setting of allogeneic HSCT, we conducted a 6-
year nationwide retrospective study in France.
Patients and Methods
Mucormycosis cases diagnosed among allogeneic HSCT
recipients in France between January 2003 and December
2008 were identiﬁed through the National Reference Centre
for Mycoses and Antifungals [8]. The MCM isolates were
identiﬁed at the local microbiology laboratory and identiﬁca-
tion was conﬁrmed at the National Reference Centre for
Mycoses and Antifungals. Cases were classiﬁed according to
current deﬁnition criteria [1]. Responses to treatment were
assessed by local physicians according to recommendations
[9]. Any death occurring in cases of stable or progressing
MCM was assessed as MCM-attributable. Graft-versus-host
disease was considered acute if it occurred before day 100
and chronic if it occurred more than 100 days after HSCT
[10].
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Statistical analysis
The day of diagnosis was deﬁned as the day on which the
ﬁrst procedure leading to diagnosis was performed. The
probability of mortality from any cause was estimated using a
Kaplan–Meier estimator and the probability of MCM-attribut-
able mortality was calculated from the usual cumulative inci-
dence estimator, with death from other causes considered
as a competing event. Associations of factors with mortality
from any cause were analysed using Cox proportional haz-
ards and cause-speciﬁc hazards models. Tests were two-
sided at a 0.05 level. Analyses were performed using the R
statistical software version 2.10.1 (R Development core
team).
Results
Epidemiology of allogeneic HSCT-associated MCM in
France
Among the 39 SFGM-TC (Socie´te´ Franc¸aise de Greffe de
Moelle et The´rapie Cellulaire) centres, 27 participated in the
study and performed 96% (6810) of the 7097 transplants
performed in France during the study period. Twenty-nine
MCM cases were identiﬁed, giving an MCM prevalence of
0.4% among allogeneic HSCT recipients in France. The MCM
was proven in 15 cases (52%) and probable in 14 cases
(48%). Culture was positive in 25 cases (86%).
Patient and MCM characteristics
Mucormycosis occurred at a median of 225 days after alloge-
neic HSCT (range: 0–2693 days). At diagnosis, 26 patients
(89%) were receiving steroids (median dose 1 mg/kg/day)
(Table 1). Ten patients (34%) had experienced a prior post-
transplant invasive fungal infection, which was proven in two
cases, probable in six, possible in two and unspeciﬁed in one
(one patient had two previous invasive fungal infections). The
MCM was a breakthrough infection in 23 cases. Nine
patients had a concomitant fungal infection.
Treatment and outcome
Three patients were not treated (autopsy diagnosis, n = 2,
palliative care, n = 1). First-line treatment was liposomal
amphotericin B (n = 23), amphotericin B deoxycholate
(n = 1) or posaconazole (n = 2). Nine patients subsequently
received posaconazole, either in combination with liposomal
amphotericin B (n = 5) or after liposomal amphotericin B
was discontinued (n = 4). Surgery was performed in 12
patients (46%), a median of 7 days (range: 0–77) after diagno-
sis. There were seven (27%) complete responses, three
(12%) partial responses and 16 failures (62%). Median follow-
up was 23 months (range: 1–87 months). Overall survival
was 34% (95% CI 21–57) at 3 months and 17% (95% CI 8–
38) at 1 year (Fig. 1a). Twenty-four patients died during fol-
low-up. Mucormycosis-attributable mortality was 59% (95%
CI 38–74) (Fig. 1b). The last death attributed to MCM
occurred 115 days after diagnosis. Other causes of death
were graft-versus-host disease (n = 4, including one com-
plete response and three partial response patients), relapse
(n = 1) and other infections (n = 2, including one complete
response patient). Five complete response patients remained
alive at a median of 708 days after MCM diagnosis (range:
398–2635 days).
Univariable analysis of variables associated with overall
mortality is displayed in Table 1. Multivariable analysis identi-
ﬁed both an age of £45 years (hazard ratio 3.70, 95% CI
1.46–9.38, p 0.006) and female gender (hazard ratio 2.97,
95% CI 1.02–8.61, p 0.045) as being associated with a higher
risk of mortality.
Discussion
We report an MCM prevalence of 0.4% among allogeneic
HSCT recipients, in line with previously reported ﬁgures
[3,11–15]. Mucormycosis was a late event after allogeneic
HSCT, in accordance with previous studies [4,7,11,13]. Most
patients in this series presented the well-established MCM
risk factors including graft-versus-host disease and a high
steroid dose [3,4,11,15]. One must consider that in alloge-
neic HSCT recipients, MCM often develops as a break-
through infection, i.e. in patients receiving an antifungal
agent. This was indeed the case for 79% of the patients in
this series and for 100% in another series [16]. Strikingly,
ten out of 23 patients (43%) with breakthrough MCM in
our series were on maintenance therapy for a prior invasive
fungal infection, most frequently invasive aspergillosis. The
development of MCM in patients with a prior fungal infec-
tion, a ﬁnding not previously reported, may be seen as the
result of the improved effectiveness of anti-Aspergillus treat-
ments in the context of persisting severe immunosuppres-
sion leading to the occurrence of subsequent infectious
complications. We report a 31% rate of pulmonary co-infec-
tion with moulds, in accordance with previous reports
[2,4,7]. This prominent co-infection rate highlights the need
for comprehensive microbiological research into the diagno-
sis of pneumonia in such patients. Mortality remains unac-
ceptably high in allogeneic HSCT recipients, as shown in this
series as well as in three recently published prospective
studies [7,11,12]. Several outcome predictors have been
reported previously [5, 17–19] but none were speciﬁcally
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assessed in allogeneic HSCT recipients. In our series, female
gender and younger age were associated with a worse prog-
nosis.
There are several limitations to our study. First, the
design is retrospective and multi-centred. Second, few autop-
sies were performed. Finally, although the present series is
TABLE 1. Patient and mucormyco-
sis characteristics and association of
characteristics with overall survival
Number HR (95% CI) p
Median age, years (min–max) 43 (3–63) 0.97 (0.95–0.99) 0.016
£45 years (%) 17 (59) 3.17 (1.30–7.73) 0.011
Male gender (%) 23 (79) 0.46 (0.17–1.25) 0.13
Haematological diagnoses (%)
Acute leukaemia 12 (41) 1*
Non-Hodgkin lymphoma and myeloma 7 (24) 0.96 (0.35–2.65) 0.94
Myelodysplastic syndromes 4 (14) 0.61 (0.17–2.21) 0.45
Others 6 (21) 0.77 (0.26–2.27) 0.63
HSC source (%)
Bone marrow 10 (36) 1*
PBSC 14 (50) 0.50 (0.20–1.25) 0.14
Cord blood 4 (14) 1.34 (0.41–4.41) 0.62
Conditioning regimen (%)
Reduced-intensity 11 (38) 1*
Myeloablative 18 (62) 1.71 (0.73–4.04) 0.22
Donor (%)
Matched related 13 (45) 1*
Unrelated 15 (52) 0.88 (0.39–1.99) 0.75
Unknown 1 (3)
GVHD (%)
Acute GVHD 2/2 (100)
Chronic extensive GVHD 20/24 (83)
Diabetes mellitus (%) 14 (48) 1.15 (0.51–2.56) 0.74
Steroid therapy at MCM diagnosis (%) 26 (89)
Steroid dose ‡ 1 mg/kg/day (%) 14 (48) 1.14 (0.51–2.55) 0.74
Neutropeniaa (%) 6/23 (26) 2.30 (0.85–6.28) 0.10
Previous post-transplant IFIb (%) 10 (34) 1.61 (0.70–3.72) 0.26
Aspergillus spp. 9
Trichoderma spp. 1
Candida spp. 1
Median time (days) between MCM diagnosis and prior IFI (range) 123 (23–392)
Ongoing antifungal treatment at MCM diagnosis (%) 23 (79)
voriconazole 11 (38)
itraconazole 4 (14)
posaconazole 3 (10)
liposomal amphotericin B and caspofungin 2 (7)
caspofungin 1 (3)
caspofungin and voriconazole 1 (3)
ﬂuconazole 1 (3)
Infection sites
lungs 20 (68)
sinus 11 (38)
others (liver, gut, mandible) 3 (10)
disseminated infection 5 (17)
Mucormycosis species
Rhizopus spp. 14 (48)
Lichtheimia spp. 6 (21)
Rhizomucor 3 (10)
Cunninghamella 2 (7)
Mucor 1 (3)
Unknown 3 (10)
Median time (days) between ﬁrst clinical signs and
MCM diagnosis (range)
11 (2–34)
Diagnosis >1 week after ﬁrst clinical symptoms (%) 21 (72) 1.36 (0.54–3.45) 0.51
Laboratory methods used for diagnosis
Sample obtained for histopathology 17 (58)
Histopathology contributing to diagnosis 17/17 (100)
Positivity of direct mycological examination 23 (79)
Positivity of mycological culture 25 (86)
Histopathology positive with negative culture 3 (10)
Concomitant fungal infection 9 (31) 0.81 (0.30–2.13) 0.66
Aspergillus spp. 6 (21)
Fusarium spp. 2 (7)
Penicillium spp. 1 (3)
Paecilomyces 1 (3)
Concomitant bacterial infection 4 (14)
Median duration of medical antifungal treatment (days) (range) 45 (3–1266)
Treatment with surgery (%) 12 (41) 0.46 (0.20–1.07) 0.072
Data are presented as a hazard ratio (HR) with its 95% conﬁdence interval (95% CI) and a p value)
GVHD, graft-versus-host disease; HSC, haematopoietic stem cell; IFI, invasive fungal infection; PBSC, peripheral
blood stem cells; MCM, mucormycosis.
*Reference category.
aPolymorphonuclear leucocytes < 500/lL.
bOne patient had two prior infections (pulmonary aspergillosis and hepatosplenic candidiasis).
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one of the largest to date to be addressed to this patient
population, the number of patients is limited.
Mucormycosis is a late, poor-prognosis infection after allo-
geneic HSCT. Because clinical symptoms are not speciﬁc,
special attention must be paid to patients with protracted
graft-versus-host disease, and particularly to those on long-
term antifungal treatment for a prior mould infection.
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